Log in to save to my catalogue

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-[alp...

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-[alp...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A692027758

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-[alpha]5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Publication information

Publisher

BioMed Central Ltd

More information

Scope and Contents

Contents

Background There are currently no pharmacological therapies to address the intellectual disability associated with Down syndrome. Excitatory/inhibitory imbalance has been hypothesized to contribute to impairments in cognitive functioning in Down syndrome. Negative modulation of the GABA.sub.A-[alpha]5 receptor is proposed as a mechanism to attenuat...

Alternative Titles

Full title

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-[alpha]5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_gale_infotracmisc_A692027758

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A692027758

Other Identifiers

ISSN

1866-1947

DOI

10.1186/s11689-022-09418-0

How to access this item